## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

## Listing of Claims:

1. (Currently amended) A compound of the Formula I:

$$\mathbb{R}^1$$
 $\mathbb{R}^1$ 
 $\mathbb$ 

Formula I

wherein:

-L- represents a double bond and r and s each represent 1 or -L- represents a triple bond and r and s each represent 0;

G is selected from O, S and NR<sup>5</sup>;

Y is selected from N and CR<sup>6</sup>:

Q<sup>1</sup> is selected from arvl and heteroarvl.

and wherein  $\mathbf{Q}^1$  is optionally substituted by one or more substituents, which may be the same or different, selected from halogeno, trifluoromethyl, trifluoromethoxy, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulfsulfinyl, (1-6C)alkylsulfsulfinyl, (1-6C)alkylglamino, di-[(1-6C)alkylglamino, (1-6C)alkylglamino, M-(1-6C)alkylcarbamoyl, N.N.di-[(1-6C)alkylcarbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkynoylamino, N-(1-6C)alkyl-(3-6C)alkynoylamino, N-(1-6C)alkyl-(1-6C)

$$-X^{1}-B^{7}$$

wherein X<sup>1</sup> is a direct bond or is selected from O and N(R<sup>9</sup>), wherein R<sup>9</sup> is hydrogen or (1-6C)alkyl, and R<sup>7</sup> is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl or di-[(1-6C)alkylamino-(1-6C)alkyl, and from a group of the formula:

 $-X^{2}-Q^{2}$ 

wherein  $X^2$  is a direct bond or is selected from O, S, SO, SO<sub>2</sub>, N(R<sup>9</sup>), CO, CH(OR<sup>9</sup>), CON(R<sup>9</sup>), N(R<sup>9</sup>)CO, N(R<sup>9</sup>)CON(R<sup>9</sup>), N(R<sup>9</sup>)N(R<sup>9</sup>), N(R<sup>9</sup>)SO<sub>2</sub>, C(R<sup>9</sup>)<sub>2</sub>O, C(R<sup>9</sup>)<sub>2</sub>S and N(R<sup>9</sup>)C(R<sup>9</sup>)<sub>2</sub>, wherein R<sup>9</sup> is hydrogen or (1-6C)alkyl, and Q<sup>2</sup> is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl-(1-6C)alkyl which optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from trifluoromethyl, trifluoromethoxy, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkyl, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkylamino, di-[(1-6C)alkylamino, di-(1-6C)alkylamino, di-

- X<sup>3</sup>- R<sup>10</sup>

wherein X³ is a direct bond or is selected from O and N(R¹¹), wherein R¹¹ is hydrogen or (1-6C)alkyl, and R¹⁰ is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, (1-6C)alkyl, (1

and any heterocyclyl group within Q<sup>2</sup> optionally bears 1 or 2 oxo or thioxo substituents;

- R is selected from hydrogen, amino, hydroxy, halogeno, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, carboxy, (1-6C)alkoxycarbonyl and N-(heterocyclyl(3-8C)cycloalkyl)carbamoyl;
- R¹ is selected from hydrogen, halogeno, trifluoromethyl, trifluoromethoxy, cyano, nitro, hydroxy, amino, mercapto, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfinyl, (1-6C)alkylamino, di-(1-6C)alkyllamino, di-(1-6C)alkylamino, di-(1-6C)alkyllamino, di-(1-6C)alkyl-(2-6C)alkynoylamino, (3-6C)alkanoylamino, di-(1-6C)alkyl-(3-6C)alkenoylamino, di-(1-6C)alkyl-(3-6C)alkynoylamino, di-(1-6C)alkyl-(3-6C)alkynoylamino, di-(1-6C)alkyl-(3-6C)alkynoylamino, di-(1-6C)alkyl-(3-6C)alkynoylamino, di-(1-6C)alkyl-(3-6C)alkynoylamino, di-(1-6C)alkyl-(3-6C)alkynoylamino, di-(1-6C)alkyl-(3-6C)alkynoylamino, di-(1-6C)alkyl-(1-6C)alkyl-(1-6C)alkynoylamino;
- R<sup>2</sup> is selected from hydrogen, halogeno, amino, hydroxy, halogeno, (1-6C)alkyl, (1-6C)alkyl, (1-6C)alkyl, (1-6C)alkylthio, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, aryl(1-6C)alkylamino, arylamino, heterocyclyl and (2-6C)alkanoylamino;

R³ is selected from hydrogen, (1-6C)alkyl, hydroxy(1-6C)alkyl, carboxy, (1-6C)alkoxycarbonyl, carbamoyl, N-(1-6C)alkylcarbamoyl, N-(1-6C)alkylcarbamoyl, N-(heterocyclyl(3-8C)cycloalkyl)carbamoyl;

R<sup>5</sup> is, independently, as defined for R<sup>4</sup> and R<sup>6</sup>, provided that R<sup>5</sup> is not halogeno:

 $\rm R^4$  and  $\rm R^6$  which may be the same or different, are selected from hydrogen, halogeno, trifluoromethyl, trifluoromethoxy, cyano, isocyano, nitro, hydroxy, mercapto, amino, formyl, carboxy, carbamoyl, sulfamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di-(1-6C)alkylamino, di-(1-6C)alkylamino, di-(2-6C)alkoxycarbonyl,  $\rm R_{\rm c}$ -(1-6C)alkyl-(2-6C)alkanoylamino, (2-6C)alkanoylamino, di-(1-6C)alkyl-(3-6C)alkanoylamino, di-(1-6C)alkyl-(3-6C)alkyl-(3-6C)alkyl-(3-6C)alkylamino, M-(1-6C)alkyl-(3-6C)alkyl-(

 $Q^4 - X^5 -$ 

wherein  $X^5$  is a direct bond or is selected from O, S, SO, SO<sub>2</sub>, N(R<sup>12</sup>), CO, CH(OR<sup>12</sup>), CON(R<sup>12</sup>), N(R<sup>12</sup>)CO, SO<sub>2</sub>N(R<sup>12</sup>), N(R<sup>12</sup>)SO<sub>2</sub>, OC(R<sup>12</sup>)<sub>2</sub>, SC(R<sup>12</sup>)<sub>2</sub> and N(R<sup>12</sup>)C(R<sup>12</sup>)<sub>2</sub>, wherein R<sup>12</sup> is hydrogen or (1-6C)alkyl, and Q<sup>4</sup> is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl, (4-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

and wherein adjacent carbon atoms in any (2-6C)alkylene chain within an  $R^4$ ,  $R^5$  or  $R^6$  substituent are optionally separated by the insertion into the chain of a group selected from O, S, SO, SO<sub>2</sub>, N(R<sup>13</sup>), CO, CH(OR<sup>13</sup>), CON(R<sup>13</sup>), N(R<sup>13</sup>)CO, SO<sub>2</sub>N(R<sup>13</sup>), N(R<sup>13</sup>)SO<sub>2</sub>, CH=CH and C=C wherein R<sup>13</sup> is hydrogen or (1-6C)alkyl,

and wherein any CH<sub>2</sub>=CH- or HC=C- group within an R<sup>4</sup>, R<sup>5</sup> or R<sup>6</sup> substituent optionally bears at the terminal CH<sub>2</sub>= or HC= position a substituent selected from halogeno, carboxy, carbamoyl, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N-N-di-[(1-6C)alkyl]carbamoyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl and di-[(1-6C)alkyl]amino-(1-6C)alkyl er and from a group of the formula:

wherein  $X^6$  is a direct bond or is selected from CO and N(R<sup>14</sup>)CO, wherein R<sup>14</sup> is hydrogen or (1-6C)alkyl, and  $Q^5$  is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl-(1-6C)alkyl,

and wherein any CH<sub>2</sub> or CH<sub>3</sub> group within a R<sup>4</sup>, R<sup>5</sup> or R<sup>6</sup> substituent optionally bears on each said CH<sub>2</sub> or CH<sub>3</sub> group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, cyano, amino, carboxy, carbamoyl, (1-6C)alkyl, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfinyl, (1-6C)alkylsulfinyl, (1-6C)alkylsulfinyl, (1-6C)alkyllamino, di-[(1-6C)alkyl]amino, (1-6C)alkyllamino, M·(1-6C)alkyllamino, m·(

$$-X^{7}-Q^{6}$$

wherein  $X^7$  is a direct bond or is selected from O, S, SO, SO<sub>2</sub>, N(R<sup>15</sup>), CO, CH(OR<sup>15</sup>), CON(R<sup>15</sup>), N(R<sup>15</sup>)CO, SO<sub>2</sub>N(R<sup>15</sup>), N(R<sup>15</sup>)SO<sub>2</sub>, C(R<sup>15</sup>)<sub>2</sub>O, C(R<sup>15</sup>)<sub>2</sub>S, and N(R<sup>15</sup>)C(R<sup>15</sup>)<sub>2</sub>, wherein R<sup>15</sup> is hydrogen or (1-6C)alkyl, and Q<sup>6</sup> is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalken

and wherein any aryl, heteroaryl, heterocyclyl, cycloalkyl or cycloalkenyl group within a substituent on R<sup>4</sup>, R<sup>5</sup> or R<sup>6</sup> optionally bears 1 or more substituents, which may be the same or different, selected from halogeno, trifluoromethyl, trifluoromethoxy, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylylithio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyljamino, (1-6C)alkoxy, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulfamoyl, N-N-di-[(1-6C)alkylsulfamoyl, (1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkyl-(1-6C)alkyl-(1-6C)alkylsulfamoyl, (1-6C)alkyl-(1-6C)alkyl-(1-6C)alkanoylamino, from a group of the formula:

wherein X<sup>8</sup> is a direct bond or is selected from O and N(R<sup>17</sup>), wherein R<sup>17</sup> is hydrogen or (1-6C)alkyl, and R<sup>16</sup> is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkyl, amino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl or (1-6C)alkoxycarbonylamino-(1-6C)alkyl, and from a group of the formula:

-X8-P16

$$-X^{9}-\Omega^{7}$$

wherein  $X^9$  is a direct bond or is selected from O, S, SO, SO $_2$ , N(R<sup>18</sup>), CO, CH(OR<sup>18</sup>), CON(R<sup>18</sup>), N(R<sup>18</sup>)SO $_2$ , C(R<sup>18</sup>) $_2$ O, C(R<sup>18</sup>) $_2$ O, C(R<sup>18</sup>) $_2$ S and  $\underline{or}$  N(R<sup>18</sup>)C(R<sup>18</sup>) $_2$ , wherein R<sup>18</sup> is hydrogen or (1-6C)alkyl, and Q<sup>7</sup> is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl which optionally bears 1 or 2 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, trifluoromethoxy, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkylamino, M-(1-6C)alkylamino, M-(1-6C)alkyl-(2-6C)alkanoylamino, M-(1-6C)alkylsulfamoyl, N.M-di-[(1-6C)alkyl-(2-6C)alkanoylamino, M-(1-6C)alkylsulfamoyl, N.M-di-[(1-6C)alkylsulfamoyl, (1-6C)alkylsulfamoyl, (1-6C)alkylsulfamoyl, (1-6C)alkyl-(1-6C)alkyl-(1-6C)alkylsulfamoyl, (1-6C)alkylsulfamoyl, (1-6C)alkylsulfamoylamino, (1-6C)alkylsulfamoyl, (1-6C)alkylsulfamoylsulfamoyl, (1-6C)alkylsulfamoylsulfamoylsulfamoylsulfamoylsulfamoylsulfamoylsulfamoylsulfamoylsulfamoylsulfamoylsulfamoylsulfamoylsulfamoy

or when G is NR<sup>5</sup>, R<sup>4</sup> and R<sup>5</sup> together with the atoms to which they are attached form a fused 5or 6- membered heteroaryl or heterocyclyl ring, and wherein said fused 5- or 6-membered ring optionally bears one or more substituents as defined for R<sup>4</sup>,

and any fused 5- or 6- membered heterocyclyl ring so formed optionally bears 1 or 2 oxo or thioxo substituents,

and wherein any heterocyclyl group within any R<sup>4</sup>, R<sup>5</sup> or R<sup>6</sup> substituent optionally bears 1 or 2 oxo or thioxo substituents; or a pharmaceutically-acceptable salt thereof; provided the compound is not 4-[-2-(6-phenylimidazo[2,1-b][1,3-thiazol-5-yl)ethenyl]-2-pyrimidinamine.

- 2. (original) A pharmaceutical composition which comprises a compound of the Formula I, or a pharmaceutically acceptable salt thereof, as defined in claim 1 in association with a pharmaceutically-acceptable diluent or carrier.
- 3. (Previously canceled)
- 4. (Previously canceled)
- (Previously canceled)

- 6. (Previously presented) A compound according to Claim 1 wherein **R** is selected from hydrogen, halogeno, carboxy, (1-6C)alkoxycarbonyl and *N*-(heterocyclyl(3-8C)cycloalkyl)carbamoyl or a pharmaceutically acceptable salt thereof.
- (Previously presented) A compound according to Claim 1 wherein R<sup>1</sup> is selected from hydrogen, amino and (1-6C)alkyl or a pharmaceutically acceptable salt thereof.
- 8. (Previously presented) A compound according to Claim 1 wherein R² is selected from hydrogen, halogeno, hydroxy, amino, (1-6C)alkylthio, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, aryl(1-6C)alkylamino, arylamino, heterocyclyl and (2-6C)alkanoylamino or a pharmaceutically acceptable salt thereof.
- 9. (Previously presented) A compound according to Claim 1 wherein R³ is selected from hydrogen, carboxy, (1-6C)alkoxycarbonyl, hydroxy(1-6C)alkyl, N-(1-6C)alkylcarbamoyl and N-(heterocyclyl(3-8C)cycloalkyl)carbamoyl or a pharmaceutically acceptable salt thereof.
- 10. (Previously presented) A compound according to Claim 1 wherein R<sup>4</sup> is hydrogen and R<sup>5</sup> is selected from (1-6C)alkyl, aryl(1-6C)alkyl, carboxy(1-6C)alkyl, heterocyclyl(1-6C)alkyl and amino(1-6C)alkyl wherein the amino group is optionally substituted by one or more (1-6C)alkyl or a pharmaceutically acceptable salt thereof.
- 11. (Canceled)
- 12. (Canceled)